Clemedi AG

Academic Poster Presentation

Clemedi AG

Tuberculini: combining targeted sequencing and machine learning to optimize antibiotic therapy in tuberculosis patients

Focus area: Diagnostics
Keywords: tuberculosis, drug resistance, AMR, diagnostics, machine learning

Introduction:
Each year, there are more than 10M new cases of tuberculosis (TB) and a steady increase in rates of drug-resistant TB (DR-TB) is observed. To reduce the spread of hard to treat DR-TB strains, novel methods to rapidly detect DR-TB and provide guidance on antibiotic efficacy are needed. Clemedi is developing a targeted sequencing pipeline “Tuberculini” to optimise treatment for drug-resistant tuberculosis. It comprises reagent kits and machine learning algorithms, which are described here. 

Methods:
14’190 publicly available WGS data sets with annotated antibiotic susceptibility information were aligned against the tuberculosis reference genome using bwa and variants called using freebayes on genomic regions part of the Tuberculini enrichment panel (incl. 138 genes covering 208 kilo-bases). 95% of panel had to be covered at least 20-fold to include the data in the machine learning set. We chose the best performing combination from 11 model/parameter combinations, based on 10-fold cross validation. 

Results:
We could generate models for a total of 8 antibiotics: Isoniazid, Rifampicin, Ethambutol, Pyrazinamide, Ofloxacin, Capreomycin, Kanamycin, Amikacin. Both sensitivity and specificity in predicting antibiotic resistance from whole genome sequences of isolates were > 90% for 6 antibiotics and > 95% for 2 antibiotics (see figure 1). Models that performed best were regularized logistic regression and support vector machines. Discussion: Implementation of Tuberculini can help improve patient management by providing comprehensive information about drug susceptibility and resistance within 24-48 hours. This allows a rapid switch from empirical to targeted therapy, shortens isolation period and time to recovery and reduces mortality and morbidity.

Authors:
Dr. Sebastian Dümcke (Clemedi AG; Universität Zürich)
Dr. Prajwal (Clemedi AG; Universität Zürich)
Prof. Thorsten Buch (Insitut für Labortierkunde, Universität Zürich)
Dr. Peter Keller Insititut für Infektionskrankheiten, Universistät Bern)

Partnering | You can meet the author Dr. Sebastian Dümcke virtually during the AMR Conference week:

Main contact (corresponding author):

Dr. Sebastian Dümcke
CEO
Clemedi AG

Please fill out the form below to get in touch with the author(s)